Try GOLD - Free
NCDs Alarm Demands Bold Steps
Bio Spectrum
|March 2017
India is first country to develop targets, indicators to reduce global premature deaths from NCDs by 25 per cent by 2025.

One out of four Indians face the risk of dying from non-communicable diseases (NCDs) before they turn 70. NCDs represent the largest cause of death, in India as well as globally, with the percentage of premature deaths caused by cancer, heart disease, diabetes and lung infection increasing steeply from 42 in 2012 to 70 in 2015, according to WHO.
NCDs affect all age groups. And the WHO report that “16 million of all deaths attributed to non-communicable diseases occur before the age of 70. Of these “premature” deaths, 82 per cent occurred in low and middle income countries. Children, adults and the elderly are all vulnerable to the risk factors” throws out the assumption that the ailment is often associated with older age groups.
NCDs are defined as chronic diseases that are not transmitted from one person to another. They are characterised by slow progression and long duration. The four main types of NCDs are cardiovascular diseases (like heart attacks and stroke), cancer, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma) and diabetes. These four diseases are largely caused by behavioral risk factors like tobacco use, unhealthy diet, physical inactivity and alcohol use. Additional risk factors like obesity, high blood pressure, high levels of cholesterol and blood glucose are tied to lifestyle choices.
This story is from the March 2017 edition of Bio Spectrum.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 9,500+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bio Spectrum

Bio Spectrum
WHO certifies Suriname malaria-free
Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).
1 min
August 2025

Bio Spectrum
Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation
Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.
1 min
August 2025
Bio Spectrum
Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab
Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.
1 min
August 2025
Bio Spectrum
Illumina buys SomaLogic for $425 M to accelerate proteomics business
Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.
1 min
August 2025

Bio Spectrum
Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26
Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.
1 min
August 2025
Bio Spectrum
WHO highlights risks associated with use of semaglutide medicines
The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.
1 min
August 2025

Bio Spectrum
Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin
Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.
1 min
August 2025

Bio Spectrum
AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru
AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.
1 min
August 2025

Bio Spectrum
Novo Nordisk launches injectable Semaglutide for weight management in India
Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.
1 min
August 2025

Bio Spectrum
Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?
India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.
12 mins
August 2025
Translate
Change font size